

CORRIGENDUM

Acute myeloid leukemia targets for bispecific antibodies

SS Hoseini and NK Cheung

Blood Cancer Journal (2017) 7, e552; doi:10.1038/bcj.2017.35; published online 14 April 2017

Correction to: *Blood Cancer Journal* (2017) 7, e522; doi:10.1038/bcj.2017.2; published online 3 February 2017

Following the online publication of this article, the authors noted that the following funding information needed to be included:

This work was supported through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Also, Table 3 requires correction of few numbers. The correction has already been made to the html version of the article.

Table 3. Characteristics of bispecific antibodies generated for acute myeloid leukemia

	MW (kDa)	Affinity (K_D) (nM)		EC_{50} pM	Clone	
		Effector (CD3, etc)	Target (CD33, etc)			
			Parent clone			Bispecific format
CD33 × CD3 BiTE AMG330 ⁹	55	5.1	-	8	0.4-3	-
CD33 × CD3 scBsTaFv ^{17,146,147}	60	-	0.1	10-100	15	DRB2 (CD33)
CD33 × CD16 chemically conjugated ²³	-	-	-	-	-	251 (CD33), 3G8 (CD16)
CD16 × 33 BiKE ¹⁴⁸⁻¹⁵⁰	55	20 (scFv)	-	-	-	NM3E2 (CD16)
CD33 × CD16 × CD33 sctb ²⁹	90	45.1 ± 4.3	-	7.9 ± 1.1	1.8-18	K132 (CD33), 3G8 (CD16)
CD33 × CD16 × CD19 sctb ³⁰	90	49 ± 5.2	-	CD33 (29 ± 1.9)	7.2 ± 2	K132 (CD33), 3G8 (CD16)
CD123 × CD16 × CD33 sctb ³¹	90	21.7 ± 1.8	-	CD33 (17.8 ± 2.2), CD123 (18.8 ± 0.9)	21-118	K132 (CD33), 3G8 (CD16), CD123 (from phage (151))
CD123 × CD3 BIF ^{152,153}	140	10	0.01-0.05	0.1	10	12F1 (CD123), UCHT1 (CD3)
CD3 × CD123 DART ⁴²	59	9 ± 2.3	-	0.13 ± 0.01	0.17	7G3 (CD123)
CD123 × CD16 bsscFv ¹⁵¹	60	49 ± 5	-	4.5-101	211-364	3G8 (CD16), CD123 (from phage (151))
CD15 × CD64 chemically conjugated ⁵⁴	-	-	-	-	-	PM81 (CD15), 32 (CD64)
CD33 × CD64 chemically conjugated ^{32,34}	-	-	-	-	-	H22 (CD64), 251 (CD33)
CD16 × CD33 chemically conjugated ²³	-	-	-	-	-	3G8 (CD16), 251 (CD33)
CD3 × CD33 modular retargeting system ¹⁹	-	-	0.1	-	-	MT-301 (CD3), DRB2 (CD33)
CD33 × CD3 BiFab ^{a,68}	~ 100	-	7	Similar to their parental clones	25-445	Mutated hM195 (CD33), and UCHT1 (CD3)
Anti-CD3 Fab' × anti-CD13Fab' chemically conjugated ⁵¹	100-110	-	-	-	-	OKT3 (CD3), My7 (CD13)
CD30 × CD16A TandAb ⁶⁰	105-110	0.39	17.2	9.3	35 800	LSIV21 (CD16), HRS-3 (CD30)
CD30 × CD16A bispecific diabody ⁶⁰	60	35	17.2	194	751 000	LSIV21 (CD16), HRS-3 (CD30)
WT1 × CD3 BiTE ^{46,47}	-	-	-	0.2	-	ESK1 (WT1), L2K (CD3)
CD20 × CD47 DVD-Ig	-	-	CD47 (3.1)	CD47 (48-60)	-	2B8 (CD20), B6H12.2 (CD47)
CLL1 × CD3 BiFab ^{a,68}	~100	-	6.1	Similar to their parental clones	2.1-41	Mutated 1075.7 (CLL1), and UCHT1 (CD3)
FLT3 × CD3 BiTE ⁷¹	-	-	-	-	-	4G8 (FLT3), UCHT1 (CD3)
FLT3 × CD3 Fabsc ⁷¹	87	-	-	-	-	4G8 (FLT3), BV10 (FLT3), UCHT1 (CD3), OKT3 (CD3), BMA031 (CD3)
VEGF × Ang-2 CrossMab ^{80,81}	-	-	Bevacizumab (< 0.1)Ang-2 (0.2)	Bevacizumab (< 0.1)Ang-2 (0.2)	-	Bevacizumab = humanized A.4.6.1 (VEGF) and LC06 (Ang-2)

^aBiFab antibodies were generated by conjugating the antigen-binding fragments (Fab) of two antibodies using bio-orthogonal chemical linkers.